Showing 103 results
Archivistische beschrijving![[F] Case Study Ripple Mapping Dr. Brenyo - YouTube .pdf](/uploads/r/null/9/2/9/929d8fb29ba1409bc17b362a86b01fadcdb19ae8139c0ea37c0baab5020e5533/b25c39c5-177e-484f-a727-bdc18739803b-_E__Case_Study_Ripple_Mapping_Dr._Brenyo_-_YouTube__142.jpg)
[F] Case Study Ripple Mapping Dr. Brenyo - YouTube .pdf
![[B] PEPfAR Scientific Advisory Board..pdf](/uploads/r/null/5/c/a/5ca11145b76ae47d37acde2b06405847768ecbe212b0b6d8c8c96ef4e3f649ac/4cdff724-b569-418e-bd76-4ca371a4c21e-_B__PEPfAR_Scientific_Advisory_Board._142.jpg)
[B] PEPfAR Scientific Advisory Board..pdf
![[I] THE UNION’S 2020 ANNUAL AWARDS RECOGNISE SIGNIFICANT CONTRIBUTIONS TO LUNG HEALTH.pdf](/uploads/r/null/4/0/8/408a4461c49beab8028feab1f60005bcb5075bb0baabde9be258c73cfe75e91f/e0651179-afbb-4ed9-895d-0c45cc0f078b-_I__THE_UNION_S_2020_ANNUAL_AWARDS_RECOGNISE_SIGNIFICANT_CONTRIBUTIONS_TO_LUNG_HEALTH_142.jpg)
[I] THE UNION’S 2020 ANNUAL AWARDS RECOGNISE SIGNIFICANT CONTRIBUTIONS TO LUNG HEALTH.pdf
![[C] South African HIV Society ART guidelines for adults .pdf](/uploads/r/null/f/9/d/f9d0c9ccba1cef71b267ddb0f69b8fa03aa58e98e7b8ceabe8a71f3a71667ebc/b3ba5934-e574-4c83-9a03-70182e830d35-_C__South_African_HIV_Society_ART_guidelines_for_adults__142.jpg)
[C] South African HIV Society ART guidelines for adults .pdf
![[E] WHO Guidelines for the treatment of latent tuberculosis – 2018..pdf](/uploads/r/null/7/4/b/74b3751b0dd67a6c1ec3d4188f4aace19a1453fb09b2aecbcd467a5c8319a04b/a281fca4-bd95-40bf-aa48-8628d0853c54-_E__WHO_Guidelines_for_the_treatment_of_latent_tuberculosis_-_2018._142.jpg)
[E] WHO Guidelines for the treatment of latent tuberculosis – 2018..pdf
![[G] Guidelines for the Treatment of Latent Tuberculosis Infection Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 Morbidity and Mortality Weekly Report February 14 2020.pdf](/uploads/r/null/4/6/e/46ed66d453821f0ddccadce5494a4e14439887fe2a0f1a6659e92729d89545c6/e42813dc-061f-4c04-89f6-a6dc91eafef5-_G__Guidelines_for_the_Treatment_of_Latent_Tuberculosis_Infection_Recommendations_from_the_National_Tuberculosis_Controllers_Association_and_CDC__2020_Morbidity_and_Mortality_Weekly_Report_February_14_2020_142.jpg)
[G] Guidelines for the Treatment of Latent Tuberculosis Infection Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 Morbidity and Mortality Weekly Report February 14 2020.pdf
![[Dii] British HIV association guidelines for the management of TB HIV co-infection in adults updated 2019.pdf](/uploads/r/null/b/c/1/bc14c2c5bfbd6c908be5532eb3baca5a63d0d2b7df401029c3412e3b8902767f/73f830d9-2c0f-411c-a9e3-400920683796-_Dii__British_HIV_association_guidelines_for_the_management_of_TB_HIV_co-infection_in_adults_updated_2019_142.jpg)
[Dii] British HIV association guidelines for the management of TB HIV co-infection in adults updated 2019.pdf
![[Ei] UK Health Service Commissioning.pdf](/uploads/r/null/2/6/a/26afc5d8068ca0049c04fd2487741e6172f4544ebb4ebaaa95d1d7734b692d77/ce77c157-7e52-4df0-8872-8105cefe27e5-_Ei__UK_Health_Service_Commissioning_142.jpg)
[Ei] UK Health Service Commissioning.pdf
![[I] EMA Summary of opinion Kalydeco.pdf](/uploads/r/null/6/9/f/69f5b6684c69eaf2ab9e4e024465979536dc4a61a3e03362c92a9472a7406f5e/77efc402-d85b-4c97-9d44-b53f7a027c7e-_I__EMA_Summary_of_opinion_Kalydeco_142.jpg)
[I] EMA Summary of opinion Kalydeco.pdf
![[A] EMA approval document for Ivacaftor, 2015.pdf](/uploads/r/null/8/9/6/8969010570da34537eaf78e175287d4a5135f40e254bc792688c197e09de38bb/67df1c03-b7f5-4133-b31b-d679fff38b87-_A__EMA_approval_document_for_Ivacaftor__2015_142.jpg)
[A] EMA approval document for Ivacaftor, 2015.pdf
![[Eiv] UK Health Service Commissioning NHS Wales, 29 November 2019.pdf](/uploads/r/null/a/4/e/a4e14d3dd97ba41ed4fe68bca72e3f806509ade0510180dac06803ba4516968a/3669d6ef-2ea8-4649-bc32-b694596c911c-_Eiv__UK_Health_Service_Commissioning_NHS_Wales__29_November_2019_142.jpg)
[Eiv] UK Health Service Commissioning NHS Wales, 29 November 2019.pdf
![[Gii] Health Service Commissioning of TrikaftaKaftrio NHS Wales.pdf](/uploads/r/null/7/4/9/7499a3f3f1f1dcef0858488e8a0fc40f7d3c1974bdd7896bd1e4f552741e1707/10964f43-4c31-4fea-9e46-a0a4fa9b0f1a-_Gii__Health_Service_Commissioning_of_TrikaftaKaftrio_NHS_Wales_142.jpg)
[Gii] Health Service Commissioning of TrikaftaKaftrio NHS Wales.pdf
![[Giv] Health Service Commissioning of TrikaftaKaftrio NHS Scotland.pdf](/uploads/r/null/0/9/0/09048357648e2b8fc29f11fffb97b91e09a24886e98fbddc0dca4b182f65cd18/a5b03f20-5da0-4b70-87bd-9fc74875f2a2-_Giv__Health_Service_Commissioning_of_TrikaftaKaftrio_NHS_Scotland_142.jpg)
[Giv] Health Service Commissioning of TrikaftaKaftrio NHS Scotland.pdf
![[Gi] Health Service Commissioning of TrikaftaKaftrio NHS England.pdf](/uploads/r/null/5/6/7/5679d95879085b5cf3c340b33165aac0aa4a93dc172e884f5cb5f21775c07feb/e1b1cfef-9479-4860-aedf-4cc23f19e733-_Gi__Health_Service_Commissioning_of_TrikaftaKaftrio_NHS_England_142.jpg)
[Gi] Health Service Commissioning of TrikaftaKaftrio NHS England.pdf
![[Giii] Health Service Commissioning of TrikaftaKaftrio Northern Ireland.pdf](/uploads/r/null/c/f/b/cfb1b31923f41e01a108288ec61634772d5a1dc918bb35888dda3f0ae8e33eaa/d0bfc5e3-cfe6-4be6-951d-d2286ffc7dad-_Giii__Health_Service_Commissioning_of_TrikaftaKaftrio_Northern_Ireland_142.jpg)
[Giii] Health Service Commissioning of TrikaftaKaftrio Northern Ireland.pdf
![[Ci] EMA Orkambi approval documents Approval for use in patients 12 years and older.pdf](/uploads/r/null/c/5/8/c5899e08d80d55921956995ba6877c3eb46975d987de0c6d571fb9cde8bff91b/52f73e0d-7dc5-4b7b-9f47-a8f415418a42-_Ci__EMA_Orkambi_approval_documents_Approval_for_use_in_patients_12_years_and_older_142.jpg)
[Ci] EMA Orkambi approval documents Approval for use in patients 12 years and older.pdf
![[Cii] EMA Orkambi approval documents Approval for use in patients 6 years and older.pdf](/uploads/r/null/0/e/6/0e6ea321eb24fd572a1dab7b64b3bf165cea74705c8afa1478fd0e62a2a60231/75b65d32-fa41-4f2f-83c1-b48de27c6f8b-_Cii__EMA_Orkambi_approval_documents_Approval_for_use_in_patients_6_years_and_older_142.jpg)
[Cii] EMA Orkambi approval documents Approval for use in patients 6 years and older.pdf
![[D] EMA Assessment report.pdf](/uploads/r/null/6/1/b/61bd7e3ace00f4101c3601b1d53bad03a2c9e9b770a336a0d838b82fafdea053/c052d84e-5516-4b95-ad04-c02d9eb3ff73-_D__EMA_Assessment_report_142.jpg)
[D] EMA Assessment report.pdf
![[Eii] UK Health Service Commissioning Northern Ireland, Department of Health, 29 October 2019 .pdf](/uploads/r/null/6/2/1/6217606d78cb47a70ba649d901098f8dd9cb60aa47299a74fc0b6b6cef5fb5c0/221787e5-dcde-45e4-b712-386be039ba0e-_Eii__UK_Health_Service_Commissioning_Northern_Ireland__Department_of_Health__29_October_2019__142.jpg)
[Eii] UK Health Service Commissioning Northern Ireland, Department of Health, 29 October 2019 .pdf
![[Eiii] UK Health Service Commissioning Scottish Health Secretary, 12 September 2019 .pdf](/uploads/r/null/5/3/d/53d65645a7722315d8b8f2e1d86c0e3f4efc6b73b0a7cfeeede93de9264c94fd/9e72b03a-ecce-4260-a9bc-a973970785b5-_Eiii__UK_Health_Service_Commissioning_Scottish_Health_Secretary__12_September_2019__142.jpg)
[Eiii] UK Health Service Commissioning Scottish Health Secretary, 12 September 2019 .pdf